

Increasing value and reducing waste in biomedical research: Who's listening?

Moher, David; Glasziou, Paul; Chalmers, Iain; Nasser, Mona; Bossuyt, Patrick M M; Korevaar, Daniël A.; Graham, Ian D.; Ravaud, Philippe; Boutron, Isabelle

Published in:
The Lancet

DOI:
[10.1016/S0140-6736\(15\)00307-4](https://doi.org/10.1016/S0140-6736(15)00307-4)

Licence:
CC BY-NC-ND

[Link to output in Bond University research repository.](#)

Recommended citation(APA):

Moher, D., Glasziou, P., Chalmers, I., Nasser, M., Bossuyt, P. M. M., Korevaar, D. A., Graham, I. D., Ravaud, P., & Boutron, I. (2016). Increasing value and reducing waste in biomedical research: Who's listening? *The Lancet*, 387(10027), 1573-1586. [https://doi.org/10.1016/S0140-6736\(15\)00307-4](https://doi.org/10.1016/S0140-6736(15)00307-4)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository coordinator.

1 **Increasing value, reducing waste in biomedical research: who's listening?**

2

3 David Moher^{1,2}, PhD; Paul Glasziou³, FRACGP; Iain Chalmers⁴, DSc; Mona Nasser⁵, DDS; Patrick

4 M.M. Bossuyt⁶, PhD; Daniël A. Korevaar⁶, MD; Ian D. Graham^{1,2}, PhD, FCAHS; Philippe Ravaud⁷,

5 MD; Isabelle Boutron⁷, MD

6

7 ¹Clinical Epidemiology Program, Ottawa Hospital Research Institute; ² School of Epidemiology,

8 Public Health and Preventive Medicine, University of Ottawa; ³Centre for Research in Evidence

9 Based Practice, Bond University, Robina, QLD, Australia; ⁴James Lind Initiative, Oxford, UK;

10 ⁵Peninsula Dental School, Plymouth University, Plymouth, England; ⁶Department of Clinical

11 Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, University of

12 Amsterdam, (UvA), Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands; ⁷METHODS Team,

13 Epidemiology and Statistics Sorbonne Paris Cité, Research Center INSERM UMR 1153, University

14 of Paris, France

15 Date – 1st May 2015

16 Word count –

17 Tables – 3; Figures – 1; Appendix (possibly included only on www.researchwaste.net)

18

19

20

21

22 Address for correspondence:

23 David Moher

24 Clinical Epidemiology Program, Ottawa Hospital Research Institute. The Ottawa Hospital, General

25 Campus. 501 Smyth Rd, Room L1288. Ottawa, ON, K1H 8L6. Canada

26 email: dmoher@ohri.ca

27 Twitter: [@dmoher](https://twitter.com/dmoher)

28 **Abstract**

29 The biomedical research complex has been estimated to consume almost a quarter of a
30 trillion dollars every year. Unfortunately, there is evidence that a high proportion of this sum is
31 avoidably wasted. Last year the *Lancet* published a series of 5 papers showing how dividends from
32 the investment in research might be increased from the relevance and priorities of the questions
33 being asked, to how the research is designed, conducted, and reported. Seventeen recommendations
34 were addressed to five main stakeholders - funders, regulators, journals, academic institutions, and
35 researchers. This paper provides some initial observations on the possible impacts of the series. It
36 appears to have provoked several important discussions and has appeared on the agendas of several
37 key players. There are also examples of individual initiatives illustrating ways of reducing waste and
38 increasing value in biomedical research. This momentum is likely to move more strongly across
39 stakeholder groups, if more collaborative relationships evolve among key players; more important
40 work is required to increase research value. A forthcoming meeting in Edinburgh will provide a
41 forum within which to foster the collaboration needed.

42

43

44 **Introduction**

45 More than 30 years ago the adverse clinical consequences of biased under- reporting of
46 research were clearly documented ¹, and non-publication remains hugely problematic.²⁻⁵ Non-
47 publication is bad value for funders, who could double research output by ensuring all the studies
48 they fund are published, and it puts patients and clinicians at a substantial disadvantage in making
49 informed decisions about healthcare.⁶ Trial registration, supported by the International Committee
50 of Medical Editors (ICMJE)⁷, has helped^{8,9} although it is clearly not a panacea.^{10,11} Other related
51 initiatives, such as the Alltrials initiative (www.alltrials.net) and the Institute of Medicine's recent
52 report on data sharing¹² are working to ensure that the results of all trials are reported and their data
53 made available.

54 Non-publication was one of four contributors to the estimated 85% of current research
55 funding that Chalmers and Glasziou suggested in 2009 were being avoidably “wasted”¹³ across the
56 entire biomedical research spectrum (e.g., clinical, health services, and basic science). Evidence of
57 the degree and avoidability of waste in research production at each of their 4-stage model (see Figure
58 1) has strengthened: imbalanced research question selection, poor study design^{14,15} and execution,
59 non-publication¹⁶ and poor reporting¹⁷. In addition to 295 citations, the 2009 paper led the National
60 Institute of Health Research (NIHR) in England to establish a working group to monitor and plan
61 actions, with regular meetings and an annual closed conference. Their “Adding Value in Research”
62 programme added an additional stage aiming to ensure that NIHR funded research: 1. addresses
63 questions relevant to clinicians, patients and the public; 2. uses appropriate design and methods; 3. is
64 delivered efficiently; 4. results in accessible full publication; and 5. produces unbiased and usable
65 reports. They developed a quality improvement tool¹⁸ for these 5 stages to identify common themes
66 and examples of good practice across their programmes. For example, since 2013, NIHR has
67 required applicants for support of new primary research should reference an existing systematic

68 review “as well as including reference to any relevant literature published subsequent to that
69 systematic review” or where no such systematic review exists applicants should undertake to review
70 the relevant evidence (using a methodology that systematically identifies, critically appraises and then
71 synthesises the available evidence) which “must also include reference to relevant on-going studies,
72 e.g. from trial registries”.¹⁹

73 Last year the *Lancet* published a series of articles (“Increasing value: reducing waste”)
74 extending the 2009 analysis to 50 journal pages, with over 40 authors²⁰⁻²⁴ focused on the 5 NIHR
75 stages (see Figure 1). As the commissioning editors noted “Our belief is that research funders,
76 scientific societies, school and university teachers, professional medical associations, and scientific
77 publishers (and their editors) can use this Series as an opportunity to examine more forensically why
78 they are doing what they do ... and whether they are getting the most value for the time and money
79 invested in science.”.²⁵

80 The series, and an accompanying symposium²⁶, provided a voluminous body of evidence of
81 the problems in biomedical research, along with 17 recommendations (see Table 1) to help increase
82 its value, covering funders, regulators, journals, academic institutions, and researchers. The problems
83 include (although they are not limited to) whether planned research met the needs of end users.²⁷⁻²⁹

84 Initial media attention included coverage by several newspapers including the leading
85 German paper *Der Spiegel*³⁰, although there has been almost no response from German researchers
86 or organizations.³¹ Several research funders responded through meetings, working parties, and some
87 changes of processes (see Funders section below). In the year since their publication the five articles
88 have been downloaded 46,596 times from the *Lancet.com* and *Science Direct.com* websites. The
89 five articles have already been cited 113 times (Scopus); were all in the top 5% of all articles indexed
90 by Scopus; and their Altmetric scores (social media) all ranked above the 98th percentile (of more

91 than 3 million articles scored) including 589 tweets (about 20% of which were by healthcare
92 professionals).

93 This follow-up paper offers an overview of the initial influence of the series. Prior to
94 conducting the assessment a protocol was developed outlining the key players, the methods of our
95 investigation, including sampling frames (see Panel 1 with more detail in Appendix 1). The primary
96 focus was to examine what funders, regulators, journals, academic institutions, and researchers are
97 doing, and plan to do, to address waste in biomedical research.

98 **Funders**

99 A few funders have already responded to the series. In May 2014, The French Institute of
100 Health and Medical Research INSERM (Institut National de la Santé et de la Recherche Médicale),
101 in conjunction with the EQ

102 UATOR network, organised a 1-day conference in Paris on “Improving reporting to
103 decrease the waste of research” with the head of the Wellcome Trust and NIHR’s HTA programme
104 among the speakers (video of all sessions is available on the EQUATOR website.³² The series was
105 included in recent discussions of INSERM’s strategic plan for 2016-2020, and was presented at the
106 annual meeting of INSERM team leaders.³³ In Australia, the National Health and Medical Research
107 Council (NHMRC) set up a working party to review all the recommendations in the series³⁴,
108 updating and modifying their procedures, and also featured an opening session on “Adding Value,
109 Reducing Waste” at their 2014 annual scientific meeting³⁵ The series was also on the agenda of the
110 Heads of International Research Organizations (HIRO) group’s meeting in 2014.

111 We are also heartened that concern about poor replicability and quality of much animal and
112 other preclinical research³⁶ has prompted some influential organisations to draw attention to and

113 address these concerns. For example, a meeting on ‘Reproducibility and reliability of biomedical
114 research’ was convened jointly by the UK Academy of Medical Sciences, the UK Medical Research
115 Council, the Wellcome Trust and the Biotechnology and Biological Sciences Research Council. The
116 National Centre for the Replacement, Refinement and Reduction of Animals in Research
117 (www.nc3rs.org.uk) has supported three international meetings (in Nijmegen, Edinburgh and
118 Washington DC) on systematic reviews of animal research, and this year held an international
119 meeting on biased under-reporting of animal research³⁷, bringing together several relevant groups
120 targeted in the series. Whether or not the Lancet series had any role in these initiatives, they are very
121 welcome.

122 The examination of the funder’s websites (see Methods panel) indicates that most funders
123 are not explicit about many of the key issues, making it challenging to evaluate them. The NIHR had
124 a number of innovative and exemplary features, such as requirements for systematic reviews before
125 embarking on additional primary studies, active monitoring of ongoing studies, and its own journal.
126 For other funders, the picture was more mixed (see Table 2). Most required trial registration, but few
127 required systematic reviews prior to additional primary studies, or mentioned reporting guidelines,
128 such as CONSORT, or the EQUATOR Network. Regarding conduct of systematic reviews before
129 additional primary research, most funding organisations only required systematic reviews before
130 considering funding future clinical trials. NIHR was an exception in that they ask for a systematic
131 review for any research projects being submitted to them (see Table 1; 3rd recommendation from
132 series). Only two of these funders had a substantial targeted research scheme that addressed priority
133 questions for clinicians and patients: the NIHR’s Health Technology Assessment program, and the
134 Patient-Centered Outcomes Research Institute (PCORI) in the United States.

135 To maximize research value funders may want to consider ways to enhance their funding
136 priorities in line with existing (regional, national, and international) priority setting initiatives (See
137 Table 1; 2nd recommendation). Similarly, funders may want to enhance efforts to ensure that
138 wherever possible protocols are developed using relevant guidance, such as SPIRIT for randomized
139 trials and PRISMA-P for systematic reviews (see: www.equator-network.org/), and that the research
140 they fund is registered in a relevant repository (e.g., World Health Organization’s International
141 Clinical Trials Registry Platform - <http://www.who.int/ictrp/en/>, and PROSPERO) (See Table 1;
142 4th recommendation). For example, a review of 75 recently funded randomized trial protocols at one
143 granting agency showed they often did not provide adequate information about allocation sequence
144 generation (13% missing) and concealment (19% missing): important characteristics of well
145 conducted randomized trials.³⁸ Funders could also consider stronger policies to support (guidance,
146 education, and infrastructure) and enforce (incentives and penalties) publication of all research, open
147 access, and data sharing.

148 **Regulators**

149 Regulators can help here by not providing ethics approval of protocols that are scientifically
150 inadequate. Research proposals that are scientifically poor are, by definition, ethically inadequate.
151 For example, the guidance for researchers issued by the newly established Health Research
152 Authority (HRA)³⁹ in the UK now states “Any project should build on a review of current
153 knowledge. Replication to check the validity of previous research is justified, but unnecessary
154 duplication is unethical.”

155 On the other hand, research regulators can reduce waste resulting from inefficiencies in
156 research regulation. Some of these result from hyper-regulation of low risk non-interventionist
157 research, such as many descriptive surveys. Following a report⁴⁰ from the Academy of Medical

158 Sciences in the UK, the HRA is now addressing this problem. As a result, proportionate measures of
159 assessing research proposals have been introduced that take account of the plausible risks associated
160 with the research proposals being considered.

161 Some research regulators have also taken steps to reduce the problem of biased under-
162 reporting of research (see Table 1; 14th recommendation). In the UK, a favourable ethics opinion
163 for proposed clinical trials will not now be granted unless the proposed trial has been registered
164 publicly.⁴¹ Following pressure from the Alltrials campaign, the European Medicines Agency has
165 now committed to make available all clinical study reports (see Table 1; 5th and 13th
166 recommendations) of research leading to marketing licences for new drugs.⁴²

167 **Journals**

168 Given that more than half of the reports of clinical trials do not set their results in the
169 context of the totality of evidence²⁴, journals have much work to do to improve this situation. They
170 can achieve this by providing specific guidance on their websites about this crucial feature and
171 providing similar guidance to peer reviewers. In response to the series, the Lancet strengthened its
172 requirement to put research into context (see Table 1; 3rd recommendation).⁴³ From the beginning of
173 this year, all research papers submitted to any journal in the Lancet family must include a ‘Research
174 in context’ panel. The editors expressed their “hope that increasing the prominence of putting
175 research into context in the submission and publication stages will help researchers, institutions and
176 funders make decisions earlier in the process on which research questions to address and fund.”.
177 Other journals have made similar efforts, such as panels asking authors ‘what this paper adds’.
178 Something more explicit, such as the research in context panel might be more helpful.

179 Based on our interviews with journals editors (see Methods panel) the Lancet series has been
180 an impetus for reflection and change among some editors. It has been discussed internally during in-
181 house editorial meetings, at an editorial board retreat of one journal and is on the agenda for
182 discussions with other editorial boards. The series has also been on the agenda of the influential
183 editorial groups, such as ICMJE, along with other ongoing initiatives, such as the Institute of
184 Medicine's recent report on data sharing.¹² Some journals have already acted on the series. For
185 example, PLoS Medicine commissioned an editorial on how open access can reduce waste.⁴⁴ Other
186 concurrent initiatives focused on reducing research waste, not directly attributable to the series, are
187 also underway. For example, a large group of rehabilitation medicine editors signed up collectively to
188 mandate the use of reporting guidelines in their journals.⁴⁵ This policy is likely to introduce a strong
189 incentive to prospective authors across this content area to use reporting guidelines. Other fields are
190 starting to implement similar strong guidance.⁴⁶

191 The results of examining the journals websites (see Methods panel) indicates there is wide
192 variability of information contained on journal websites and the language used across journals (see
193 Figure 2). This is likely to confuse prospective authors, particularly those early on in their research
194 careers and those whose first language is not English. While journals want to maintain their
195 uniqueness, and emphasize particular issues important to them, it might be useful to consider some
196 items, perhaps particularly those related to the recommendations in the series, as core information,
197 and unambiguous language that could be included across all journal websites. This might help
198 improve matters for journals, prospective authors, and readers.

199 One immediate goal could be for every journal to explicitly support use of reporting
200 guidelines (see Table 1; 17th recommendation). The evidence indicates that their use is associated
201 with increases in the completeness of reporting clinical trials.⁴⁸ Approximately half of the websites

202 mentioned reporting guidelines which is a similar proportion to that reported by Hirst and Altman
203 in 2012.⁴⁹ Far fewer journal websites explicitly mentioned the EQUATOR Network and few
204 mentioned the use of systematic reviews in the context of reporting the main results of their
205 research (see Table 1; 3rd recommendation).

206 Journals can also add value to their websites by explicitly asking authors to provide more
207 information about their methods particularly the interventions used or details of participants. For
208 example, few (11%) reports from a sample of 255 cancer trials provided sufficient information about
209 the interventions studied⁵⁰ to allow clinicians to use the results in practice.⁵¹ Across the 10 questions
210 used to assess the websites the results did not vary substantially by journal impact factor (< 5; ≥ 5).

211 **Academic Institutions**

212 We are aware of very little explicit attention by academic institutions to the Lancet series.
213 One exception has been in Iran, where a group of academics are running a series of workshops on
214 the Lancet series. Two workshops on “Biomedical research: increasing value, reducing waste’ were
215 run in February 2015 for Directors of Clinical Research Centers, research vice chancellors, and
216 Director Generals of Research Affairs of Medical Universities of North West Universities of Iran. A
217 final national workshop is planned for the research deputies of all 50 Medical Universities of Iran.⁵²

218 Based on our e-mail survey (see Methods panel) we received complete responses from only
219 26 of the 100 invited universities. We found that most (n=20) schools have a policy to register
220 clinical trials in a publically accessible trial registry and to make full study reports available (n=19),
221 but such policies are rare for protocols (n=5), analytical algorithms (n=5), and raw data (n=5). Two
222 of the 26 universities indicated not having an institutional policy for any of these five elements (see
223 Table 1; e.g., 12th and 14th recommendations).

224 Only five medical schools reported having a policy to make all study protocols publically
225 available. At Duke University, for example, “all approved study protocols are available through the
226 School of Medicine’s electronic IRB [*Institutional Review Board*] pathway”, but such a repository for
227 study protocols seems rare elsewhere. In contrast, prospective registration of clinical trials in a
228 publically accessible trial register is enforced by almost all institutions we surveyed. Although
229 registration appears common among ‘top’ institutions, the extent to which this policy happens
230 across less prestigious academic institutions is unclear. Trial registration has been required by the
231 ICMJE since 2005⁷, and also some governmental institutions, such as FDA in the US, require
232 registration of all clinical trials.⁷ Despite these policies, only about half of all published trials are
233 currently being registered.⁵⁴ At Duke University “registration at ClinicalTrials.gov is required before
234 IRB approval, and registration record completion is required before IRB close-out”. These examples
235 highlight the importance of regulation to help maximize best research practice.

236 Up to half of all initiated clinical trials remain unpublished.⁵⁵ The Food and Drug
237 Administration (FDA), in the United States, requires posting of clinical trial results in
238 ClinicalTrials.gov within one year after study completion, but this is done for less than a quarter of
239 trials falling within FDA’s mandatory reporting rules⁵⁶, possibly due to lack of enforcement. This
240 indicates the important role of universities in further enforcing the publication of all trial results. The
241 majority of the responding deans said they have a policy to make publically available full publications
242 of studies performed at their institution (see Table 1; 17th recommendation). The University of
243 Sydney is currently in the final stages of establishing an open access policy which “will make
244 publications available whenever copyright/archiving policies allow through its external access
245 repository, no later than 12 months after the date of publication. Where access to the full text of
246 collected scholarly works is not permitted by the publisher, publication of metadata and a link to the
247 published work will be made openly available”. At the University of Groningen, “full publications

248 are typically published in its final version in the University Repository and thus largely publically
249 available”.

250 Policies to make raw data and analytical algorithms publically available seem much rarer,
251 although individual universities show promising initiatives (see Table 1; 5th and 14th
252 recommendations). The University of Sydney has a “research data registry and Electronic Lab
253 Notebook platform, both of which enable the publication of metadata (i.e., data about data - data
254 that describes and gives information about other data) and data sets”. It states that “Researchers
255 should make completed research data sets openly available for re-use by other researchers, unless
256 this is prevented by the requirements of legislation or University policy, or ethical, contractual or
257 confidentially obligations. If open access is not possible due to legal or policy reasons, researchers
258 should make metadata openly available”.

259 Other universities have less explicit policies. Cambridge University, in the United Kingdom,
260 for example, explicitly “encourages researchers to be as open as possible in discussing work with
261 other researchers and with the public. Once results have been published, the University expects
262 researchers to make available relevant data and materials to other researchers, on request”. At the
263 University of Bristol, “researchers can make study protocols, raw data and analytical algorithms
264 publically available at the institutional data repository”. Beyond the stated policies there is no data on
265 whether and how the universities monitor the implementation of any of these policies.

266 The slow uptake of some of the recommendations by academic institutions is unfortunate,
267 as a considerable proportion of all biomedical research resources go to universities⁵⁷. One
268 explanation may be the fact that university policies on these issues are rarely defined on a nationwide
269 or even global level, making it difficult to coordinate policies. This can be illustrated by the large
270 variety in the surveyed universities’ policies to make study materials publically available.

271 **Researchers**

272 Motivated by the principle that it is unethical, unscientific, and wasteful to embark on
273 research without systematically reviewing evidence of what is already known, particularly when the
274 research involves people or animals, three Scandinavian researchers⁵⁸ convened and inaugurated an
275 international Evidence-Based Research (EBR) Network at the end of 2014. The EBR Network will
276 urge funders, regulators, researchers, academic institutions, and journals to implement the changes
277 needed to promote evidence-based research. Initiatives such as Trial Forge⁵⁹, and the Clinical Trials
278 Transformation Initiative⁶⁰ both aiming to improve the efficiencies of trial conduct, should also help
279 researchers maximize the efficiencies when conducting clinical trials (see Table 1; 10th
280 recommendation).

281 To gauge further the researcher community about the series we surveyed them (see Methods
282 panel). Most researchers agreed that the series was important to increase research value. However,
283 basic scientists and clinical researchers had notably different perceptions of the concept of waste in
284 research. For example, some basic scientists disagreed with the concept and believe waste was less
285 important in their field (e.g., “[...] to state that 85% of research funding is wasted is an insult to
286 current research efforts”; “There is no [...] waste in pure, basic science”). Some were concerned by
287 the risk of a negative impact of the series on the societal view of the value of research, which could
288 result in decreased funding. The reluctance of basic researchers to face waste in research in their
289 field contrasts with the evidence of the lack of reproducibility of basic and pre-clinical research.^{5,62}

290 Most researchers endorsed the series recommendations. Nevertheless, they identified some
291 barriers to increasing research value (see Table 3). Barriers to protocol registration and data sharing
292 included the fear of inappropriate use of data, issues related to patient confidentiality, the protection
293 of original researchers’ efforts, and the risk of having their ideas stolen by others. Some also

294 considered that adherence to these recommendations could decrease researchers' autonomy and be
295 an obstacle to scientific discovery (e.g., "In basic science, there is a great need for flexibility to
296 modify the protocol in response to the latest finding. Too rigorous control on the planning of
297 experiments would simply kill the last nerve in basic research"; "Research is not a car factory").

298 Lack of expertise and appropriate support were also important barriers to performing
299 systematic reviews before planning additional studies. Some researchers expressed some concern
300 about the emergence of several quality constraints adding many discrete tasks (e.g., protocol
301 registration, adherence to reporting guidelines, data sharing etc.) that would create a cumulative and
302 discouraging burden for researchers (e.g., "We can't overly restrain creative scientists with
303 organizational rules without burdening their work"). In fact, although adherence to these
304 recommendations should have a positive collective impact for patients and researchers, perhaps
305 researchers should be rewarded for implementing them. Finally, researchers identified important
306 structural factors involved in waste in research such as the top-down funding system with an
307 inappropriate identification of priorities, a questionable peer-review and selection process, the ever-
308 growing "red tape" in research, and a reward system based on quantity of publications and journal
309 impact factor rather than on quality. It is important to take into consideration these barriers and
310 provide appropriate education, incentives, and support to improve researchers' compliance with
311 these guidelines and increase research value. Nevertheless several researchers in the field of basic
312 science have taken the lack of reproducibility and waste in research very seriously and initiatives are
313 already underway to facilitate the implementation of these guidelines.⁶³

314 **Looking to the Future**

315 The overall response to the 2014 series might be summed up as – some gratifying actions,
316 but much, much more to be done. From a bibliometric and social media perspective, the series has

317 gained some traction, which is encouraging. Recognition of the problems described in the series, and
318 dialogue about the recommendations, and possible ways to monitor progress are important first
319 steps. However, if we are to avoid the well known problem of failing to implement research
320 knowledge into practice⁶⁴, we will need to use systematically planned knowledge translation strategies
321 including the use of theory-based strategies⁶⁵ to influence research practice, programs, and policies
322 of the five included groups, and others. A good starting point may be to re-visit the series'
323 recommendations and consider ways of monitoring of increased research value (see Table 1).

324 Across the five groups our investigation has revealed nuggets of innovation and leadership,
325 and indications of potential change, all of which need to be harnessed and sustained. Historically,
326 the stakeholders have venues to talk and act within their own silos, such as the ICMJE for editors
327 and HIRO for funders. However, we are unaware of any venue in which these groups collectively
328 engage to discuss and cross pollinate ideas, or promote better research practice. The paradox is that
329 the problems outlined in the series are large and complex (e.g., there are likely large systemic and
330 cultural differences between preclinical and clinical researchers, and others, such as health services
331 and populations health researchers, in how problematic they see waste or how they think it should
332 be reduced) and no one group is responsible for addressing them. Harnessing research value may be
333 optimized through more collaborative efforts. One immediate venue to help begin the dialogue is
334 the forthcoming REWARD/EQUATOR conference ([http://researchwaste.net/research-
335 wasteequator-conference/](http://researchwaste.net/research-wasteequator-conference/)), envisaged as an annual forum to monitor progress and exchange ideas
336 on improving the entire research system. The structure of the meeting has been set up deliberately to
337 help promote and harness collaboration between all of the sectorial groups, and others, and will
338 specifically include a meeting of several networks interested in improvement of at least one of the 5
339 stages.

340 All five targeted groups have a role to play in increasing research value. Some argue that the
341 most effective strategy for maximizing research value may be through the leadership of funders and
342 regulators. Funders can use funding policies to support recommendations in the series and provide
343 guidance to researchers on how to minimize waste. For example, the National Institutes of Health
344 offers training in ‘Responsible Conduct of Research’
345 (<http://grants.nih.gov/training/responsibleconduct.htm>), an emphasis reflected in initiatives of
346 some professional bodies, such as the American Psychological Association
347 (<http://apa.org/research/responsible/index.aspx>). Funders can also hold back a proportion of
348 grant funding for research that has not yet been made publically available, to bring about better
349 value. Regulators have the authority and enforce change in keeping with the series
350 recommendations.⁴² Research ethics boards, for example, could play a greater role in checking that it
351 has been demonstrated that more research in an area is needed and helping to ensure that all
352 relevant studies are appropriately registered (see Table 1; 14th recommendation). Funders can employ
353 strong financial incentives, such as holding back a proportion of grant funding for research that is
354 not published or made publically available, to bring about better value. They can also use funding
355 policies to support the series recommendations and provide guidance to researchers on how to
356 minimize waste.

357 Others argue that academic institutions are ideally placed to lead the movement to enhance
358 research value. They are training subsequent generations of researchers, some of whom migrate to
359 other places of employment, such as journals, funders, and academic institutions For example,
360 perhaps universities could employ a new professional - publications officer - to help researchers,
361 their staff, and trainees.⁶⁶ Publication officers could also help researchers adhere to policies of
362 funders and journals, such as registering their studies at inception and using reporting guidelines to

363 report their research. Other innovations could also be integrated into the role of publications
364 officers, including helping researchers when developing research protocols.⁶⁷

365 Another strategy that might be considered is setting adherence targets for each of the series'
366 17 recommendations and monitoring progress towards achieving the targets. Would it be
367 unreasonable to consider annual increases in research value, say by 10% over the next decade? For
368 example, a 2012 survey⁴⁹ of journals' instructions to peer reviewers shows that reference to or
369 recommendations to use reporting guidelines during peer review was rare (19 of 116 journals
370 assessed; 16%). Positive incremental change could be observing at least a 10% improvement in
371 guidance to peer reviewers in the 116 journals initially surveyed. More active dissemination, in
372 keeping with the series recommendations, might involve journal organizations, such as ICMJE and
373 the World Association of Medical Editors, promoting use of reporting guidelines by peer reviewers
374 and authors. This might constitute part of a toolkit for groups affected by reporting research. More
375 generally, increases in research value can cut across stakeholders and dimensions of research (see
376 Table 1). These issues along with a general discussion about infrastructure needed to facilitate and
377 monitor change in research value, and ways to fund it, will be discussed during the forthcoming
378 REWARD/EQUATOR meeting in Edinburgh ([http://researchwaste.net/research-wasteequator-
379 conference/](http://researchwaste.net/research-wasteequator-conference/)) which is planned as a series of meetings to bring together funders, editors, and
380 research organisations together with groups working on methods to reduce research waste..

381 Perhaps it is also time to reconsider how the entire research awards system works? It has
382 been in place for a considerable time and the current state of biomedical research suggests a
383 different set of metrics and currencies may be needed to increase the value of research investment
384 (see Table 1; 12th, 15th, and 17th recommendations). During the waste launch symposium some
385 argued that the current reward system is conservative and not open to new ideas. Alternatives could

386 be discussed, piloted, evaluated, and, implemented if they bring better research value.^{68,69} The need
387 for a paradigm shift in the research reward system is also something else that could be discussed at
388 the forthcoming REWARD/EQUATOR meeting.

389 Our initial observations are based, in part, on examining websites which were often difficult
390 to navigate. Similarly, it is possible that we missed information or that some of the content has been
391 modified since we examined it. For example, on some journal websites ‘instructions to authors’ are
392 modified at the beginning of the calendar year. The survey response rates were also lower than we
393 would have liked requiring more cautious interpretation.

394 This overview is a starting point. The plan is to publish more in-depth assessments of several
395 of the stakeholder groups examined and encourage others to do likewise. Several of the issues
396 reported here will be part of the deliberations at the forthcoming REWARD/EQUATOR meeting.
397 The meeting will be a central point for funders, regulators, journals, academic institutions,
398 researchers, and others, to help increase the value of the enormous investments made in biomedical
399 research. We are all responsible for helping to ensure that all research is planned, conducted and
400 reported to such high standards that it is of value to all. Everyone deserves a guarantee of reliable
401 evidence resulting from the global research endeavours.

402

403 **Contributorship**

404

405 DM coordinated the project, wrote the first draft of the introduction and discussion, and with IG

406 completed the assessment of the journals, including the editor interviews and initial draft; PG, MN,

407 and IC completed the funders assessment and initial draft; PMMB and DAK completed the

408 academic institutions assessment and draft; and IB and PR completed the researchers (authors)

409 assessment and draft. All authors provided feedback on subsequent drafts of the paper.

410 **Acknowledgements**

411 We wish to acknowledge the help and support of Becky Skidmore, Bryn Robert Belanger, Manosilah

412 Yoganathan, and Raymond Daniel.

413 Dr. Moher is funded by a University Research Chair.

414 **References**

- 415 1. Hemminki E. Study of information submitted by drug companies to licensing authorities. *Br*
416 *Med J* 1980 Mar 22;**280**(6217):833–6. [PMID: 7370687]
- 417 2. Simes RJ. Publication bias: the case for an international registry of clinical trials. *J Clin Oncol*
418 1986 Oct;**4**(10):1529–41. [PMID: 3760920]
- 419 3. Chapman SJ, Shelton B, Mahmood H, Fitzgerald JE, Harrison EM, Bhangu A.
420 Discontinuation and non-publication of surgical randomised controlled trials: observational
421 study. *BMJ* 2014;**349**:g6870. [PMID: 25491195]
- 422 4. Hudson KL, Collins FS. Sharing and reporting the results of clinical trials. *JAMA* 2015 Jan
423 27;**313**(4):355–6. [PMID: 25408371]
- 424 5. Sena ES, van der Worp HB, Bath PM, Howells DW, Macleod MR. Publication bias in reports
425 of animal stroke studies leads to major overstatement of efficacy. *PLoS Biol* 2010
426 Mar;**8**(3):e1000344. [PMID: 20361022]
- 427 6. Liberati A. An unfinished trip through uncertainties. *BMJ* 2004 Feb 26;**328**(7438):531
- 428 7. De Angelis C, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the
429 International Committee of Medical Journal Editors. *CMAJ* 2004 Sep 14;**171**(6):606–7.
430 [PMID: 15367465]
- 431 8. Zarin DA, Tse T, Ide NC. Trial Registration at ClinicalTrials.gov between May and October
432 2005. *N Engl J Med* 2005 Dec 29;**353**(26):2779–87. [PMID: 16382064]
- 433 9. Emdin CA, Odutayo A, Hsiao AJ, et al. Association between randomised trial evidence and
434 global burden of disease: cross sectional study (Epidemiological Study of Randomized Trials-
435 ESORT). *BMJ* 2015;**350**:h117. [PMID: 25630558]
- 436 10. Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. Comparison of registered and
437 published primary outcomes in randomized controlled trials. *JAMA* 2009 Sep 2;**302**(9):977–
438 84. [PMID: 19724045]
- 439 11. Ramagopalan S, Skingsley AP, Handunnetthi L, et al. Prevalence of primary outcome changes
440 in clinical trials registered on ClinicalTrials.gov: a cross-sectional study. *F1000Res* 2014;**3**:77.
441 [PMID: 25075294]
- 442 12. Institute of Medicine. Discussion framework for clinical trial data sharing: guiding principles,
443 elements, and activities. [Internet]. Available at:
444 [http://www.iom.edu/Reports/2014/Discussion-Framework-for-Clinical-Trial-Data-](http://www.iom.edu/Reports/2014/Discussion-Framework-for-Clinical-Trial-Data-Sharing.aspx)
445 [Sharing.aspx](http://www.iom.edu/Reports/2014/Discussion-Framework-for-Clinical-Trial-Data-Sharing.aspx). Last Accessed: 14-2-2015.
- 446 13. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence.
447 *Lancet*. 2009 Jul 4;**374**(9683):86-9

- 448 14. Yordanov, et al Avoidable waste of research related to inadequate methods in clinical trials.
449 BMJ 2015;350:h809
- 450 15. Hirst JA, Howick J, Aronson JK, Roberts N, Koshiaris C, et al. (2014) The Need for
451 Randomization in Animal Trials: An Overview of Systematic Reviews. PLoS ONE 9(6):
452 e98856. doi:10.1371/journal.pone.0098856
- 453 16. Blumle A, Meerpohl JJ, Schumacher M, von Elm E (2014) Fate of clinical research studies
454 after ethical approval – follow-up of study protocols until publication PLoS One 9: e87184
- 455 17. Grant SP1, Mayo-Wilson E, Melendez-Torres GJ, Montgomery P. Reporting quality of social
456 and psychological intervention trials: a systematic review of reporting guidelines and trial
457 publications. PLoS One. 2013 May 29;8(5):e65442. doi: 10.1371/journal.pone.0065442. Print
458 2013.
- 459 18. National Institute for Health Research. Adding Value in Research Quality Improvement
460 Template. [Internet]. Available at:
461 [http://www.nets.nihr.ac.uk/_data/assets/pdf_file/0008/77219/Quality-Improvement-](http://www.nets.nihr.ac.uk/_data/assets/pdf_file/0008/77219/Quality-Improvement-Template_September-2013.pdf)
462 [Template_September-2013.pdf](http://www.nets.nihr.ac.uk/_data/assets/pdf_file/0008/77219/Quality-Improvement-Template_September-2013.pdf). Last Accessed: 5-3-2015.
- 463 19. National Institute for Health Research. Guidance notes for applicants that ensure all primary
464 research is informed by a review of the existing literature. [Internet]. Available at:
465 [http://www.nets.nihr.ac.uk/_data/assets/pdf_file/0006/77217/Guidance-notes_literature-](http://www.nets.nihr.ac.uk/_data/assets/pdf_file/0006/77217/Guidance-notes_literature-review.pdf)
466 [review.pdf](http://www.nets.nihr.ac.uk/_data/assets/pdf_file/0006/77217/Guidance-notes_literature-review.pdf). Last Accessed: 5-3-2015.
- 467 20. Chalmers I, Bracken MB, Djulbegovic B, et al. How to increase value and reduce waste when
468 research priorities are set. *Lancet* 2014 Jan 11;**383**(9912):156–65. [PMID: 24411644]
- 469 21. Ioannidis JP, Greenland S, Hlatky MA, et al. Increasing value and reducing waste in research
470 design, conduct, and analysis. *Lancet* 2014 Jan 11;**383**(9912):166–75. [PMID: 24411645]
- 471 22. Al-Shahi SR, Beller E, Kagan J, et al. Increasing value and reducing waste in biomedical
472 research regulation and management. *Lancet* 2014 Jan 11;**383**(9912):176–85. [PMID:
473 24411646]
- 474 23. Chan AW, Song F, Vickers A, et al. Increasing value and reducing waste: addressing
475 inaccessible research. *Lancet* 2014 Jan 18;**383**(9913):257–66. [PMID: 24411650]
- 476 24. Glasziou P, Altman DG, Bossuyt P, et al. Reducing waste from incomplete or unusable
477 reports of biomedical research. *Lancet* 2014 Jan 18;**383**(9913):267–76. [PMID: 24411647]
- 478 25. Kleinert S, Horton R. How should medical science change? *Lancet* 2014 Jan
479 18;**383**(9913):197–8. [PMID: 24411649]
- 480 26. Symposium on the Lancet Series on Research: Increasing value, reducing waste. [Internet].
481 Available at: www.profbriefings.co.uk/dhlancet2013/. Last Accessed: 3-5-2015.

- 482 27. Frank L, Basch E, Selby JV. The PCORI perspective on patient-centered outcomes research.
483 *JAMA* 2014 Oct 15;**312**(15):1513–4. [PMID: 25167382]
- 484 28. Williamson P, Altman D, Blazeby J, Clarke M, Gargon E. Driving up the quality and relevance
485 of research through the use of agreed core outcomes. *J Health Serv Res Policy* 2012 Jan;**17**(1):1–
486 2. [PMID: 22294719]
- 487 29. Tugwell PS, Maxwell LJ, Beaton DE, et al. Deliberative Dialogue on Developing Consensus
488 on Measurement and Presentation of Patient Important Outcomes in Systematic Reviews: A
489 Preconference Meeting at OMERACT 12. *J Rheumatol* 2015 Feb 1. [PMID: 25641896]
- 490 30. Kuhrt, N. Systemkritik: Wissenschaftselite beklagt zu viel Forschungsmüll. [Internet].
491 Available at: [http://www.spiegel.de/wissenschaft/medizin/lancet-spezial-fuer-mehr-qualitaet-](http://www.spiegel.de/wissenschaft/medizin/lancet-spezial-fuer-mehr-qualitaet-in-der-wissenschaft-a-942328.html)
492 [in-der-wissenschaft-a-942328.html](http://www.spiegel.de/wissenschaft/medizin/lancet-spezial-fuer-mehr-qualitaet-in-der-wissenschaft-a-942328.html). Last Accessed: 5-3-2015.
- 493 31. Antes,G. 2015; [German Cochrane Centre].[Personal Communication].
- 494 32. EQUATOR Network. Scientific Meeting: Improving reporting to decrease the waste of
495 research. [Internet]. Available at: [http://www.equator-network.org/2014/08/06/scientific-](http://www.equator-network.org/2014/08/06/scientific-meeting-improving-reporting-to-decrease-the-waste-of-research/)
496 [meeting-improving-reporting-to-decrease-the-waste-of-research/](http://www.equator-network.org/2014/08/06/scientific-meeting-improving-reporting-to-decrease-the-waste-of-research/). Last Accessed: 5-3-2015.
- 497 33. INSERM. Plan Stratégique Inserm 2016-2020.[Internet]. Available at: [http://reunions-](http://reunions-inserm2015.com/uploads/event_member/103354/4leplanstrategique20152020.pdf.pp2-6)
498 [inserm2015.com/uploads/event_member/103354/4leplanstrategique20152020.pdf.pp2-6](http://reunions-inserm2015.com/uploads/event_member/103354/4leplanstrategique20152020.pdf.pp2-6).
499 Last Accessed: 5-3-2015.
- 500 34. Ghersi,D. 2015; [National Health and Medical Research Council].[Internet].
- 501 35. Opening Session. Increasing value, reducing waste. In National Health and Medical Research
502 Council. 3rd Annual NHMRC Symposium on Research Translation.
503 <http://www.nhmrc2014.com/programme/wednesday.php> 2014 Nov 12;
- 504 36. Begley CG, Ioannidis JPA. Reproducibility in science: improving the standard for basic and
505 pre-clinical research. *Circulation Research* 2015; doi:10.1161/circresaha.114.303819.
- 506 37. National Centre for the Replacement Refinement & Reduction of Animals in Research.
507 NC3Rs Publication Bias Workshop.[Internet]. Available at:
508 <http://www.nc3rs.org.uk/events/nc3rs-publication-bias-workshop>. Last Accessed: 5-3-2015.
- 509 38. Kyte D, Duffy H, Fletcher B, et al. Systematic evaluation of the patient-reported outcome
510 (PRO) content of clinical trial protocols. *PLoS One* 2014;**9**(10):e110229. [PMID: 25333349]
- 511 39. Health Research Authority. Guidance: specific questions that need answering when
512 considering the design of clinical trials.[Internet]. pp 1–23. Available at:
513 [http://www.hra.nhs.uk/documents/2014/05/guidance-questions-considerations-clinical-](http://www.hra.nhs.uk/documents/2014/05/guidance-questions-considerations-clinical-trials.pdf)
514 [trials.pdf](http://www.hra.nhs.uk/documents/2014/05/guidance-questions-considerations-clinical-trials.pdf). Last Accessed: 5-3-2015.
- 515 40. Academy of Medical Sciences. A new pathway for the regulation and governance of health
516 research. [Internet]. Available at: [http://www.acmedsci.ac.uk/policy/policy-projects/a-new-](http://www.acmedsci.ac.uk/policy/policy-projects/a-new-pathway-for-the-regulation-and-governance-of-health-research/)
517 [pathway-for-the-regulation-and-governance-of-health-research/](http://www.acmedsci.ac.uk/policy/policy-projects/a-new-pathway-for-the-regulation-and-governance-of-health-research/). Last Accessed: 5-3-2015.

- 518 41. Chalmers I. Health Research Authority's great leap forward on UK trial registration. *BMJ*
519 2013;**347**:f5776. [PMID: 24068744]
- 520 42. European Medicines Agency. Guide on access to unpublished documents. [Internet].
521 [http://www.ema.europa.eu/ema/pages/includes/document/open_document](http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500177739)
522 [jsp?webContentId=WC500177739](http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500177739) 2014;
- 523 43. Kleinert S, Benham L, Collingridge D, Summerskill W, Horton R. Further emphasis on
524 research in context. *Lancet* 2014 Dec 20;**384**(9961):2176–7. [PMID: 25625383]
- 525 44. Glasziou P. The role of open access in reducing waste in medical research. *PLoS Med* 2014
526 May;**11**(5):e1001651. [PMID: 24866475]
- 527 45. Chan L, Heinemann AW, Roberts J. Elevating the quality of disability and rehabilitation
528 research: mandatory use of the reporting guidelines. *Arch Phys Med Rehabil* 2014
529 Mar;**95**(3):415–7. [PMID: 24559651]
- 530 46. Clavien PA, Lillmoen KD. A new policy to implement CONSORT guidelines for surgical
531 randomized controlled trials. *Ann Surg* 2014 Dec;**260**(6):947–8. [PMID: 25386861]
- 532 47. Abridged Index Medicus (AIM or "Core Clinical") Journal Titles.[Internet]. Available at:
533 <http://www.nlm.nih.gov/bsd/aim.html>. Last Accessed: 5-3-2015.
- 534 48. Turner L, Shamseer L, Altman DG, et al. Consolidated standards of reporting trials
535 (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs)
536 published in medical journals. *Cochrane Database Syst Rev* 2012;**11**:MR000030. [PMID:
537 23152285]
- 538 49. Hirst A, Altman DG. Are peer reviewers encouraged to use reporting guidelines? A survey of
539 116 health research journals. *PLoS One* 2012;**7**(4):e35621. [PMID: 22558178]
- 540 50. Duff JM, Leather H, Walden EO, LaPlant KD, George TJ, Jr. Adequacy of published
541 oncology randomized controlled trials to provide therapeutic details needed for clinical
542 application. *J Natl Cancer Inst* 2010 May 19;**102**(10):702–5. [PMID: 20410466]
- 543 51. Dancey JE. From quality of publication to quality of care: translating trials to practice. *J Natl*
544 *Cancer Inst* 2010 May 19;**102**(10):670–1. [PMID: 20410467]
- 545 52. Pezeshki, M. 2015; Tabriz Medical School, Golgasht Avenue, Tabriz, Iran. [Personal
546 Communication].
- 547 53. The Times Higher Education. World University Rankings. [Internet]. Available at:
548 <http://www.timeshighereducation.co.uk/world-university-rankings/2013-14/world-ranking>.
549 Last Accessed: 5-3-2015.
- 550 54. van de Wetering FT, Scholten RJ, Haring T, Clarke M, Hooft L. Trial registration numbers are
551 underreported in biomedical publications. *PLoS One* 2012;**7**(11):e49599. [PMID: 23166724]

- 552 55. Song F, Parekh S, Hooper L, et al. Dissemination and publication of research findings: an
553 updated review of related biases. *Health Technol Assess* 2010 Feb;**14**(8):iii, ix–iii,193. [PMID:
554 20181324]
- 555 56. Prayle AP, Hurley MN, Smyth AR. Compliance with mandatory reporting of clinical trial
556 results on ClinicalTrials.gov: cross sectional study. *BMJ* 2012;**344**:d7373. [PMID: 22214756]
- 557 57. Dorsey ER1, de Roulet J, Thompson JP, Reminick JI, Thai A, White-Stellato Z, Beck CA,
558 George BP, Moses H 3rd. Funding of US biomedical research, 2003–2008. *JAMA*. 2010 Jan
559 13;303(2):137–43
- 560 58. Chalmers I, Nylenna M. A new network to promote evidence-based research. *Lancet* 2014
561 Nov 29;**384**(9958):1903–4. [PMID: 25435440]
- 562 59. Treweek S. Trial forge: a systematic approach to making trials more efficient. *Trials*
563 2013;**14**(Suppl 1):O121
- 564 60. Tenaerts P, Madre L, Archdeacon P, Califf RM. The Clinical Trials Transformation Initiative:
565 innovation through collaboration. *Nat Rev Drug Discov* 2014 Nov;**13**(11):797–8. [PMID:
566 25359366]
- 567 61. Boyack KW, Klavans R, Sorensen AA, Ioannidis JP. A list of highly influential biomedical
568 researchers, 1996–2011. *Eur J Clin Invest* 2013 Dec;**43**(12):1339–65. [PMID: 24134636]
- 569 62. Kilkenny C, Parsons N, Kadyszewski E, et al. Survey of the quality of experimental design,
570 statistical analysis and reporting of research using animals. *PLoS One* 2009;**4**(11):e7824.
571 [PMID: 19956596]
- 572 63. Begley CG, Ioannidis JP. Reproducibility in science: improving the standard for basic and
573 preclinical research. *Circ Res* 2015 Jan 2;**116**(1):116–26. [PMID: 25552691]
- 574 64. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the
575 United States. *N Engl J Med* 2003 Jun 26;**348**(26):2635–45. [PMID: 12826639]
- 576 65. Eccles M, Grimshaw J, Walker A, Johnston M, Pitts N. Changing the behavior of healthcare
577 professionals: the use of theory in promoting the uptake of research findings. *J Clin Epidemiol*
578 2005 Feb;**58**(2):107–12. [PMID: 15680740]
- 579 66. Moher D, Altman DG. Making medical journal articles more useful: publication officers, core
580 competencies for editors and peer reviews, and writing articles fit for purpose. Submitted
581 *PLoS Medicine* 2015.
- 582 67. Ravaud, P. Evaluation of an online writing tool based on the CONSORT: a randomized
583 controlled trial. [Internet]. Available at: [http://www.equator-network.org/wp-](http://www.equator-network.org/wp-content/uploads/2014/12/Philippe-Ravaud-Writing-Aid-Tool-Canadian-Equator-Launch.pdf)
584 [content/uploads/2014/12/Philippe-Ravaud-Writing-Aid-Tool-Canadian-Equator-Launch.pdf](http://www.equator-network.org/wp-content/uploads/2014/12/Philippe-Ravaud-Writing-Aid-Tool-Canadian-Equator-Launch.pdf).
585 Last Accessed: 5-3-2015.
- 586 68. Ioannidis JP. How to make more published research true. *PLoS Med* 2014
587 Oct;**11**(10):e1001747. [PMID: 25334033]

588 69. Ioannidis JP, Khoury MJ. Assessing value in biomedical research: the PQRST of appraisal and
589 reward. *JAMA* 2014 Aug 6;**312**(5):483–4. [PMID: 24911291]
590
591
592

593
 594
 595
 596
 597

Table 1

The Lancet series recommendations and examples of groups who can take action to discuss, endorse, and implement the recommendations and monitor progress.

#	Recommendation	Monitoring	Examples of groups who can take action
Research priorities			
1	More research on research should be done to identify factors associated with successful replication of basic research and translation to application in health care, and how to achieve the most productive ratio of basic to applied research	Periodic surveys of the distribution of funding for research and analyses of yields from basic research	EBRN, NIH, HIRO
2	Research funders should make information available about how they decide what research to support, and fund investigations of the effects of initiatives to engage potential users of research in research prioritisation	Periodic surveys of information on research funders' websites about their principles and methods used to decide what research to support	HIRO, JLA, EBRN, Cochrane
3	Research funders and regulators should demand that proposals for additional primary research are justified by systematic reviews showing what is already known, and increase funding for the required syntheses of existing evidence	Audit proposals for and reports of new primary research	HIRO
4	Research funders and research regulators should strengthen and develop sources of information about research that is in progress, ensure that they are used by researchers, insist on publication of protocols at study inception, and encourage collaboration to reduce waste	Periodic surveys of progress in publishing protocols and analyses to expose redundant research	EBRN, HIRO
Research design, conduct, and analysis			
5	Make publicly available the full protocols, analysis plans or sequence of analytical choices, and raw data for all designed and undertaken biomedical research	Proportion of reported studies with publicly available (ideally preregistered) protocol and analysis plans, and proportion with raw data and analytical algorithms publicly available within 6 months after publication of a study report	HIRO, PROSPERO, PRISMA-P, SPIRIT, clinicaltrials.gov, ISRCTN, WHO platform
6	Maximise the effect-to-bias ratio in research through defensible design and conduct standards, a well trained	Proportion of publications without conflicts of interest, as attested by declaration statements and then	Trial Forge, CTTI, HIRO, COMET, OMERACT,

	methodological research workforce, continuing professional development, and involvement of non-conflicted stakeholders	checked by reviewers; the proportion of publications with involvement of scientists who are methodologically well qualified is also important, but difficult to document	STaRChild Health
7	Reward (with funding, and academic or other recognition) reproducibility practices and reproducible research, and enable an efficient culture for replication of research	Proportion of research studies undergoing rigorous independent replication and reproducibility checks, and proportion replicated and reproduced	HIRO, ICMJE, WAME, NIH
Research regulation and management			
8	People regulating research should use their influence to reduce other causes of waste and inefficiency in research	people regulating, governing, and managing research should measure the extent to which the research they approve and manage complies with the other recommendations in this Series	Trial Forge, CTTI, Health Research Authorities, Research Ethics Boards
9	Regulators and policy makers should work with researchers, patients, and health professionals to streamline and harmonise the laws, regulations, guidelines, and processes that govern whether and how research can be done, and ensure that they are proportionate to the plausible risks associated with the research	regulators, individuals who govern and manage research, and researchers should measure and report delays and inconsistencies that result from failures to streamline and harmonise regulations	PCORI, SPOR, Patients Canada, JLA, Research Ethics Boards
10	Researchers and research managers should increase the efficiency of recruitment, retention, data monitoring, and data sharing in research through the use of research designs known to reduce inefficiencies, and do additional research to learn how efficiency can be increased	researchers and methodologists should do research to identify ways to improve the efficiency of biomedical research	Trial Forge, CTTI
11	Everyone, particularly individuals responsible for health-care systems, can help to improve the efficiency of clinical research by promoting integration of research in everyday clinical practice	people responsible for management of health-care systems or research should measure the proportions of patients who are enrolled in research	Government ministries of health, hospital CEOs, Trial Forge, CTTI
Accessibility			
12	Institutions and funders should adopt performance metrics that recognise full dissemination of research and reuse of original datasets by external researchers	assessment of the proportion of institutional and funding-agency policies that explicitly reward dissemination of study protocols, reports, and participant-level data	HIRO, Altmetric, U15 (Canada),
13	Investigators, funders, sponsors, regulators, research ethics committees, and journals should systematically develop and adopt standards for the content of	surveys of how many stakeholders adopt international standards	Alltrials, HIRO, clinicaltrials.gov, ISRCTN, WHO platform

	study protocols and full study reports, and for data sharing practices		
14	Funders, sponsors, regulators, research ethics committees, journals, and legislators should endorse and enforce study registration policies, wide availability of full study information, and sharing of participant-level data for all health research	assessment of the proportion of stakeholder policies that endorse dissemination activities, and the proportion of studies that are registered and reported with available protocols, full study reports, and participant-level data	HIRO, COPE, IRBs, ICMJE, WAME,
Reporting			
15	Funders and research institutions must shift research regulations and rewards to align with better and more complete reporting	when assessing research (or researchers), funders and research institutions should consider the accessibility of research protocols, study materials, study data, and their use by others	HIRO, individual funding agencies
16	Research funders should take responsibility for reporting infrastructure that supports good reporting and archiving	funders and research institutions should regularly report expenditures for reporting infrastructure and archiving	HIRO, individual funding agencies
17	Funders, institutions, and publishers should improve the capability and capacity of authors and reviewers in high-quality and complete reporting	researchers should use reporting guidelines, registries, archives, etc; and take up training opportunities	HIRO, CSE, EASE, EQUATOR, ICMJE, WAME, COPE CONSORT, PRISMA, STaR Child Health

598

599 Alltrials -

600 Altmetrics – Alternative metrics

601 CONSORT – Consolidated Standards of Reporting Trials

602 COPE – Committee on Publication Ethics

603 CSE - Council of Science Editors

604 CTI – Clinical Trials Transformation Initiative

605 EASE - European Association of Medical Editors

606 EBRN – Evidence Based Research Network

607 HIRO – Heads of Research Organizations

608 ICMJE – International Committee of Medical Journal Editors

609 ISRCTN - International Standard Randomised Controlled Trial Number

610 JLA – James Lind Alliance

611 NIH – National Institutes of Health

612 PRISMA – Preferred reporting items for systematic reviews and meta-analyses

613 StarChild Health -

614 U15 (Canada) – Leading research intensive universities in Canada

615 WAME - World Association of Medical Editors

616

617
618
619
620
621

Table 2

Information available on the websites of selected funding agencies with regard to some dimensions of “reducing waste of research” framework

Funders (Country)	Is there engagement with users of research in prioritizing funding for future research (R2)	Are systematic reviews a key part of the information to inform future (basic or applied) research priorities? (R3)	Does the funder require prior registration of research? If so, which types? (R4)	What is the funder’s policy on public access to data from completed research? (R13, R14)	What is the funder’s policy on public access to protocols for completed or ongoing research? (R13)	What is the overall process to set a research agenda? (R2)
National Institute for Health Research – NIHR (England)	They involve researchers, policy makers and patient’s representative. Active patient involvement is key in the process. Outline and/or full applications (depending on specific research programme and/or funding stream) are peer reviewed – this includes a Public and patient involvement (PPI) reviews . This relates to research applications. In terms of the decisions to fund applications, Programme Boards have PPI members who will consider applications from a PPI perspective and	Yes, for any type of research The funder provides funding for systematic reviews. For Health Technology Assessment (HTA) applications, any relevant and ongoing clinical trials have to be also included. There is a specific system for monitoring the conduct of clinical trials. Reviews are carried out internally by NETSCC Programmes to ensure research not duplicated within NIHR Programme portfolios (and to identify, in certain cases, where research may feed into other NIHR calls for research in commissioned areas/themed calls – the	Yes – Clinical Trials, and some other studies NETSCC-funded Patient relevant projects must register through www.controlled-trials.com onto the ISRCTN – Programme specific advice is provided regarding registration (for research application, contracting, start-up processes – this is available on website). NETSCC-funded projects which include	The rules for publishing completed research are here http://www.nihr.ac.uk/policy-and-standards/publishing-research-findings.htm <ul style="list-style-type: none"> the principal award holder submits an end-of-project report within 14 days study close. This is managed through NIHR monitoring processes to meet NIHR’s open access commitment a copy of the final manuscript is deposited with UK PubMed Central upon acceptance for publication, to be made freely available as soon as possible and in any event within six months of the journal publisher’s official date of final publication. 	All of protocols are published on the programme website.	NIHR Evaluation, Trials and Studies (NETSCC), part of NIHR programme, works with external organisations and individuals, including a public website for suggestions, to identify research questions likely to make the greatest difference in people’s health. An advisory board prioritises proposals along with checks that there is no inadvertent duplication. NETSCC is now responsible for the James Lind Alliance programme of Priority Setting Partnerships, which engages clinicians and patients in setting research priorities

	patient need.	latter is perhaps not completely clear on the website)	systematic review as part of their protocol, must register protocols on the PROSPERO database.			
Medical Research Council – MRC (United Kingdom)	For setting the research agenda stakeholder involvement is very important (includes department of health, department of international development, devolved administrations) but they don't get involved in individual funding decisions. In individual funding decisions, strong involvement of researchers and the private sector (pharma industry); very limited and selective involvement of the public and patients. Public and patients are only involved in selective projects if deemed appropriate.	No , Expert opinion seems to be the key factor. A lot of MRC funding goes to basic laboratory work. The latter requires clear rationale based on an analysis of previous work but not a systematic review per se The only proposals requiring systematic assessment of existing evidence are global health clinical trials.	Yes for clinical trials. The funding of large scale clinical trials is done through NIHR Efficacy and Mechanism Evaluation (EME) Programme so their requirements which include clinical trial registration are followed.	MRC has policies for data sharing although it emphasizes access for scientists, not the public. The research councils in UK have an overall open access policy and give universities budgets to publish completed research in an open access format, although there is flexibility.	There is no policy on protocols, only a policy for completed research beyond the requirements of sharing information as part of registering clinical trials.	There is an overall strategic plan to guide decisions about research priorities and there are specific goals and objectives for each funding panel. The strategy Board , the Research Boards and the four overview groups (Public Health, Global Health, Translation and Research Careers) are heavily involved in setting the research agenda and identifying priorities.
National Health and Medical Research Council - NHMRC (Australia)	Researchers are strongly involved. The degree of involvement of other stakeholders is unclear.	No , Expert opinion seems to be the key. No explicit mention of the need for systematic reviews prior to new primary research.	Yes. For Clinical trials only	Yes. Publication from NHMRC supported research must be deposited into an open access institutional repository within a twelve months of publication but	No. We were unable to identify a policy for access for protocols beyond the requirement to	There is an overall strategic vision and they have health care, preventive and community health and genetic committees to advise them along with clear principles:

				don't specifically mention databases.	share information as part of the registration of clinical trials.	Fairness, Transparency. Independence, Appropriateness and balance, Research community participation, Confidentiality, Impartiality, Quality and excellence.
National Institute of Health – NIH (USA)	NIH Institutes receives data and information on the burden of disease and disability from patient and advocacy groups, professional societies, and voluntary organizations. Clinicians and basic and clinical scientists provide input on scientific opportunities. NIH Institutes and Centre's advisory councils/boards made up of scientific expert and members of the public make recommendations to ICs. In the first stage of peer review, fellow researchers evaluate the scientific merit of grant applications. In the second stage, advisory councils made up of science experts and members of the public make funding recommendations to	No –NIH uses a variety of reports and data to inform these decisions but systematic reviews is not a required piece of information for future research.	Yes for Clinical Trials only.	Yes – The NIH Grants Policy Statement sets the expectation that grantees make the results and accomplishments of their activities available to the research community and to the public at large, including sharing of publications, research data, unique research resources, as well as commercialization of federally funded inventions. The NIH public access policy requires NIH funded scientists to submit final peer-reviewed journal manuscripts that arise from NIH funds to PubMed Central immediately upon acceptance for publication no later than 123 months after the official date of publication. NIH has clear data sharing policies that are part of terms and conditions of the grant. NIH's RePORTER database provides information on the results of NIH funded	No. We were unable to identify a policy for access for protocols beyond the requirement to share information as part of the registration of clinical trials.	The U.S. congress sets NIH and its institute and centers (IC) funding levels and directs NIH attention to particular areas of research interest or emphasis. The NIH Division of Coordination, Planning and Strategic Initiatives in the NIH Office of the Director identifies important areas of scientific opportunity, rising public health challenges, and gaps in knowledge that deserve special emphasis. Trans-NIH planning for the Common Fund involves broad stakeholder input from multiple scientific and public inputs. The mission of each NIH institute and center generally focus on a different disease, organ, or stage of life. The individual ICs set their own research priorities considering the following factors, IC mission, available funding, scientific needs and opportunities, gaps in funded research, burden of disease, and public health need, such as an emerging threat. Priorities are partially driven by the research community with their

	the IC.			research to the public by linking information on publications and patents arising from NIH funded projects to project abstracts and administrative information, including budget		investigator initiated proposals.
Canadian Institute for Health Research – CIHR (Canada)	<p>Strong involvement of researchers, moderate involvement of policy makers, selective or limited involvement of members of public and industry. The Investigator Initiated program uses peer reviewers to evaluate and rank which proposals should be funded. These are primarily academics/healthcare providers, however, depending on the expertise required to review the proposal can also include knowledge users (e.g., policy makers, industry representatives).</p> <p>The priority-driven research program also uses peer reviewers but each peer review</p>	<p>No, Expert opinion seems to be the key. They do encourage a systematic review for clinical trials. The specific requirements for proposals can vary between funding opportunities but the criteria for assess evidence and justification for research can include completeness of the literature review and relevance to study design/research plan.</p>	Yes, for clinical trials	<p>Yes. The Tri-Agency Open Access Policy on Publications¹(Tri-Agency or Tri-Council refers to Canada’s three Federal Research Granting Councils, CIHR, the Natural Sciences and Engineering Research Council (NSERC) and the Social Sciences and Humanities Research Council (SSHRC))requires that any publication arising from agency supported research must be deposited into an institutional or disciplinary repository that makes the manuscript freely accessible within 12 months of publication, and/or published in a journal that offers immediate open access or that offers open access on its website within 12 months.</p> <p>CIHR researchers are also required to deposit some</p>	<p>No, The Tri-Agency Open Access Policy on Publications provides policy guidance related to public access for all completed research. There is no separate policy on protocols (except for the requirements for clinical trials as specified in Chapter 11 of the TCPS-2. All fields outlined in the WHO Trial Registration Data Set (TRDS) must be completed in order for a trial to be considered fully registered. A registration with missing</p>	<p>CIHR is a health research funding organization. CIHR does not commission research of any kind for its own use. CIHR has two streams of funding: investigator initiated and priority driven. Investigator-Initiated research is researcher driven in that researchers submit proposals on subjects of their choice and not on subjects prioritized or targeted by CIHR. These proposals are peer reviewed and weighted against similar proposals and subsequently funded in order of ranking within the available budget.</p> <p>Priority-Driven Health research is designed to respond to Canada’s strategic health-related research priorities. Strategic priorities are developed by CIHR’s Governing and Science Council, by evaluating government priorities, emerging needs,</p>

	<p>committee is tailored to the specific strategic initiative competition. Depending on the scope and nature of the program these reviewers can include some combination of patients, public, academics, press, private sector representatives or health-care providers. With the Strategy for Patient-Oriented Research, for example, CIHR is gaining experience developing peer review committees with public, academic, patient, provider and private sector reviewers.</p>			<p>specific types of data in appropriate public databases immediately upon publication of research results.</p>	<p>information or uninformative fields in the TRDS is unacceptable</p>	<p>trends and important knowledge deficits in the Canadian health research landscape.</p> <p>More specifically, in order to determine how to allocate its strategic funding, CIHR develops a five-year Strategic Plan based on a number of important inputs and involving many stakeholders. Inputs include the Government of Canada Science & Technology (S&T) Strategy, Ministerial priorities and key stakeholders including patients, industry, policy makers and provincial health ministries. In addition during the strategic planning exercise, input from the public is invited through various electronic means. The latest strategic plan (Health Research Roadmap II: Capturing Innovation to Produce Better Health and Health Care for Canadians 2014-2015-2018-2019), was recently approved by CIHR's Governing Council and is posted on CIHR's website. CIHR's Institutes and their Scientific Directors are also involved, along with their communities, in helping to inform the directions of CIHR's Priority-Driven programs</p>
--	--	--	--	---	--	---

						through the design of initiatives that service the priorities of their research communities. This process often includes consultations with researchers, partners, patients, etc. Each CIHR institute also has their own strategic plan that aligns with CIHR's strategic plan (as mentioned above) and is available on CIHR's website. CIHR's Governing Council is comprised of 18 women and men who are able to contribute to the achievement of CIHR's objectives in the overall interests of Canadians; each come from a unique background and possess an outstanding skill set; reflect a range of relevant backgrounds and disciplines.
Deutsche Forschungsgemeinschaft –DFG (Germany)	<p>Researchers are involved in reviewing and making decisions. For some proposals, it goes to the joint committee that involves policy makers too.</p> <p>In the decision making process, the proposal is evaluated by voluntary reviewers (scientists) exclusively according to scientific criteria; on the basis of this expert review, it is</p>	<p>Yes for clinical trials The current state of the research field and evidence is to be presented in the proposals. For clinical trials, the structured search for evidence has to be described or systematic reviews to be referenced. The comprehensive description of the existing evidence is a key reviewing criterion. Systematic reviews can</p>	Yes for clinical trials only	<p>There are suggestions and examples for researchers on reusing research data. DFG strongly encourages researchers to have strategies to reuse data "In order to enhance the long-term archiving and curation of research data, the DFG funds projects that seek to achieve an efficient reuse of research data" but it isn't compulsory.</p>	<p>All clinical trials funded after the 1.6.2014 have to deposit the study protocol at the clinical trials registry prior to trial start but not for other study designs.</p>	<p>The DFG is the self-governing organisation for science and research in Germany. It serves all branches of science and the humanities. The chief task of the DFG is to select the best research projects by scientists and academics at universities and research institutions on a competitive basis and to finance these projects. Projects are presented by scientists and academics or by universities in a proposal dealing with their chosen topics from a particular discipline or taking an</p>

	<p>assessed by chosen members of the Review Board (scientists), and the final decision is taken by the Grants Committee. There are different Grants Committees involved for the different programmes of DFG funding. They consist of researchers, representatives of the federal and the state governments as well as from the Donors' Association for the Promotion of Sciences and the Humanities in Germany. Members of the standing review boards all elected by the scientific communities every four years.</p>	<p>be funded in the individual grants programmes.</p>				<p>interdisciplinary approach. In a multi-layered decision making process, the proposal is evaluated by voluntary reviewers exclusively according to scientific criteria; on the basis of this expert review, it is assessed by chosen members of the Review Board, and the final decision is taken by the Grants Committee. In this way, DFG funding guarantees quality-based differentiation in the German research system.</p> <p>In keeping with the DFG's concept of its role as a self-governing organisation, any eligible researcher may submit a funding proposal at any time and on any research topic. As the DFG does not specify a topic for proposals, but, instead, reacts to proposals on any topic, it promotes research primarily in what is known as "response mode", thereby complementing the agenda driven and programme oriented funding by the ministry of research and education. (BMBF) in Germany.</p>
--	---	---	--	--	--	---

622
623
624
625
626

Table 3
Barriers to reducing waste in research identified by researchers
and facilitators to increasing research value

#	Recommendations	Barriers identified	Facilitators
3	Perform a systematic review of all available evidence before planning a study	Basic Researchers (BR): “The primary barrier is the vast amount of information that has to be surveyed combined with reduced time to linger and concentrate on a given project in university institutions in general.” BR: “There is no such thing as all available evidence. What constitutes evidence for a particular study is integral part of the conceptualization of the study. Different people have legitimately different methods in using evidence. Too much evidence, some of which is just bad data, can be paralyzing and prevent innovation.” Clinical Researchers (CR): “Very expensive and time consuming to do full systematic reviews and most researchers aren't good at it.”	Funders to make systematic review a condition for grant submission; Funders and journals to collaborate on developing educational toolkits for “research in context”; Institutions to provide methodological and logistical support to researcher to perform systematic reviews
14	Systematically register study protocol at inception	BR: “A registry will add extra work and a collection of information that will not correspond to the actual experiment.” CR: Lack of knowledge in how and when to register.	Develop appropriate register for basic scientists; Develop researcher toolkits for use of the World Health Organization’s International Clinical Trials Registry Platform, PROSPERO, and other relevant repositories.
5	Make the full protocol publicly available	BR: This demand would make it impossible for smaller groups to come to new break throughs even though it is their idea CR: Takes time and innovative ideas might be hard to publish once it’s on the public domain	To develop appropriate repository for basic scientists; to provide specific funding and logistical support to researchers to make these documents and data available; funders, institutions,
5	Make the analysis plan publicly available	BR: Obviously these questions are not for basic research but for applied clinical research CR: I would love to do this, but usually there is too little time to complete the analysis plan	
15	Systematically	BR: Time waste, need lot of time to write negative	


	make their results publicly available	experiments. CR: Negative results are less likely to have enthusiasm for publication.	editors to reward researchers making the protocol, analysis plan, results, raw data publicly available.
5	Make raw data publicly available	BR: Lack of suitable repositories-lack of funding to establish these. CR: This would create many problems of confidentiality etc. that would require redacting and involve a lot of "wasted" time. There is also probably reluctance to give access to such data because others may use them for their own purposes. CR: massively sharing data could lead to inappropriate use, as the context of data collection, the objective of the study, are necessary to understand their meaning.	

628 Figure 1: Stages in research production (stage 3 – dashed box – added to 2009 model by NIHR).
629
630 Please see PowerPoint slide (Waste initial observations figure 1).

631
632
633
634
635
636
637
638
639

Figure 2

Frequency of responses to 10 questions from websites of 119 core clinical journals included in Medline’s Abridged Index Medicus (<http://www.nlm.nih.gov/bsd/aim.html>).



640
641
642
643

- Q1 – Does journal ITA explicitly mention reporting guidelines (such as CONSORT)?
- Q2 – Does journal ITAs explicitly mention the EQUATOR Network?
- Q3 – Does journal ITA explicitly mention clinical trial, systematic review, or other registration (such as PROSPERO; indicate which one(s) specifically)?
- Q4 – Does the journal ITA mention use of systematic reviews as part of reporting main study results (e.g., item 23 of CONSORT**)?
- Q5 – Does the journal’s Instruction to Authors recommend authors to go to the ICMJE Website for guidance?
- Q6 – Does the journal support publishing “research on research”, such as a “methods and reporting section”?
- Q7 – Has the journal published editorials highlighting the series, other pieces on waste, duplication, reporting guidelines, registration, other topics related to increasing value?
- Q8 – Does the journal provide support for good reporting infrastructure?
Ex: study registries, data repositories, other
- Q9 – Does the journal mention open access?
- Q10 – Does the journal have a policy on public access to data from completed research?